16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Glucose dysregulation promotes oncogenesis in human bladder cancer by regulating autophagy and YAP1/TAZ expression

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glucose dysregulation is strongly correlated with cancer development, and cancer is prevalent in patients with Type 2 diabetes (T2D). We aimed to elucidate the mechanism underlying autophagy in response to glucose dysregulation in human bladder cancer (BC). 220 BC patients were included in this retrospective study. The expression of YAP1, TAZ and AMPK, EMT‐associated markers, and autophagy marker proteins was analysed by immunohistochemistry, western blotting, and quantitative real‐time PCR (qPCR). Further, T24 and UMUC‐3 BC cells were cultured in media with different glucose concentrations, and the expression of YAP1, TAZ, AMPK and EMT‐associated markers, and autophagy marker proteins was analysed by western blotting and qPCR. Autophagy was observed by immunofluorescence and electron microscopy. BC cell viability was tested using MTT assays. A xenograft nude mouse model of diabetes was used to evaluate tumour growth, metastasis and survival. A poorer pathologic grade and tumour‐node‐metastasis stage were observed in patients with BC with comorbid T2D than in others with BC. YAP1 and TAZ were upregulated in BC samples from patients with T2D. Mechanistically, high glucose (HG) promoted BC progression both in vitro and in vivo and inhibited autophagy. Specifically, various autophagy marker proteins and AMPK were negatively regulated under HG conditions and correlated with YAP1 and TAZ expression. These results demonstrate that HG inhibits autophagy and promotes cancer development in BC. YAP1/TAZ/AMPK signalling plays a crucial role in regulating glucose dysregulation during autophagy. Targeting these effectors exhibits therapeutic significance and can serve as prognostic markers in BC patients with T2D.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer Statistics, 2021

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

            The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a "population-based" to a more "personalized" approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as "what's new" in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93-99. © 2017 American Cancer Society.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism

              The altered metabolic programme of cancer cells facilitates their cell-autonomous proliferation and survival. In normal cells, signal transduction pathways control core cellular functions, including metabolism, to couple the signals from exogenous growth factors, cytokines or hormones to adaptive changes in cell physiology. The ubiquitous, growth factor-regulated phosphoinositide 3-kinase (PI3K)-AKT signalling network has diverse downstream effects on cellular metabolism, through either direct regulation of nutrient transporters and metabolic enzymes or the control of transcription factors that regulate the expression of key components of metabolic pathways. Aberrant activation of this signalling network is one of the most frequent events in human cancer and serves to disconnect the control of cell growth, survival and metabolism from exogenous growth stimuli. Here we discuss our current understanding of the molecular events controlling cellular metabolism downstream of PI3K and AKT and of how these events couple two major hallmarks of cancer: growth factor independence through oncogenic signalling and metabolic reprogramming to support cell survival and proliferation.
                Bookmark

                Author and article information

                Contributors
                bubuxiong1989@outlook.com
                23444176@qq.com
                yuzx515@163.com
                Journal
                J Cell Mol Med
                J Cell Mol Med
                10.1111/(ISSN)1582-4934
                JCMM
                Journal of Cellular and Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1582-1838
                1582-4934
                04 September 2023
                December 2023
                : 27
                : 23 ( doiID: 10.1111/jcmm.v27.23 )
                : 3744-3759
                Affiliations
                [ 1 ] Department of Urology, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China
                [ 2 ] Department of Oncology of The First Affiliated Hospital and Tumor Institute Hainan Medical University Haikou Hainan China
                [ 3 ] Department of Urology and Chest Surgery The People Hospital of Tongjiang Bazhong Sichuan China
                [ 4 ] Department of Oncology and Hematology The People Hospital of Tongjiang Bazhong Sichuan China
                [ 5 ] Cancer Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital Hospital of the University of Electronic Science and Technology of China Chengdu China
                [ 6 ] Department of Urology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China
                [ 7 ] Department of Neurology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China
                [ 8 ] Department of Obstetrics and Gynecology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China
                Author notes
                [*] [* ] Correspondence

                Shi Li, Department of Urology, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

                Email: bubuxiong1989@ 123456outlook.com

                Hua Zhu, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

                Email: 23444176@ 123456qq.com

                Zhixian Yu, Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

                Email: yuzx515@ 123456163.com

                Author information
                https://orcid.org/0000-0001-5261-2269
                Article
                JCMM17943 JCMM-03-2023-035.R4
                10.1111/jcmm.17943
                10718143
                37665055
                7c9664ad-845c-4fef-bd74-77f658a73f28
                © 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 08 August 2023
                : 08 March 2023
                : 24 August 2023
                Page count
                Figures: 7, Tables: 2, Pages: 16, Words: 7446
                Funding
                Funded by: China Scholarship Council , doi 10.13039/501100004543;
                Award ID: 202108330204
                Funded by: Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province
                Award ID: 2022E10022
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 81902555
                Funded by: Wenzhou Municipal Science and Technology Bureau , doi 10.13039/501100007194;
                Award ID: Y2020150
                Funded by: Youth Science and Technology Talent Innovation Project of Hainan Provincial Association for Science and Technology
                Award ID: QCXM202017
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                December 2023
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.5 mode:remove_FC converted:13.12.2023

                Molecular medicine
                ampk,autophagy,bladder cancer,high glucose,yap1/taz
                Molecular medicine
                ampk, autophagy, bladder cancer, high glucose, yap1/taz

                Comments

                Comment on this article